Ratings by Guggenheim (Paul Jeng)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/14/2026 | Adagene Inc | ADAG | Maintain | Buy (Buy) |
|
Details | ||
| 4/28/2026 | Corbus Pharmaceuticals | CRBP | New Coverage | Buy (N/A) |
10.08 (9.01) |
-10.62% | Details | |
| 4/14/2026 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Adagene Inc | ADAG | Maintain | Buy (N/A) |
|
Details | ||
| 11/24/2025 | Adagene Inc | ADAG | New Coverage | Buy (N/A) |
1.80 (3.59) |
99.44% | Details | |
| 11/18/2025 | Immatics | IMTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2025 | Immunocore Holdings | IMCR | New Coverage | Neutral (N/A) |
33.81 (34.96) |
3.4% | Details | |
| 9/18/2025 | Immatics | IMTX | New Coverage | Buy (N/A) |
6.00 (9.59) |
59.83% | Details | |
| 9/18/2025 | Context Therapeutics | CNTX | New Coverage | Buy (N/A) |
0.85 (0.60) |
-29.41% | Details | |
| 9/17/2025 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
24.72 (36.01) |
45.67% | Details | |
| 7/29/2020 | Artara Therapeutics Inc. | TARA | New Coverage | Buy (N/A) |
27.45 (4.10) |
-85.06% | Details |
